your partner in preclinical research

Latest Posts

> 2019 May

Urosphere/ Urolead and Institut Curie will present their last results at the AACR meeting, Denver: Bladder Cancer: Transforming the Field.

    Fruit of a long term collaboration, Urosphere and its affiliate Urolead (Toulouse) and Institut Curie (Paris) will present a fully characterized biobank of PDXs from bladder cancers and its relevant use as a drug discovery platform. The results will be presented in poster session A, on Sunday, May 19th and in plenary session 5, on Monday, May 20th.
Title: Establishment of a panel of patient-derived tumor xenograft models recapitulating molecular heterogeneity and drug response of muscle-invasive bladder tumors.
Isabelle Bernard-Pierrot, Institut Curie, Paris, France, poster board number A24
Title: PDX and genetic mouse models for deciphering signaling pathways in bladder cancer.
François R. Radvanyi, Institut Curie, Paris, France, Plenary Session 5: Models for Discovery Please, do not hesitate to attend these sessions and contact us.    

Read more

> 2019 Mar

Urosphere will be present at the European Association of Urology congress 2019.


    Urosphere will present a poster at the EAU congress (from 15 to 19 March 2019). Poster 500:Patard PM et al.,Characterization of bladder organoid cultures from healthy and cancer tissues.  It will be a pleasure to meet you during the EAU congress. Don't hesitate to contact us.

Read more

> 2017 Oct

AACR-NIC-EORTC conference in Philadelphia, from Oct 26th to Oct 31st.

Urosphere / Urolead will be represented by Repositive’s CEO Fiona Nielsen at the AACR-NIC-EORTC conference in Philadelphia, from Oct 26th to Oct 31st. Come and meet her at booth 817.

Read more

> 2017 Oct

Part of the Repositive PDX comsortium.

Urosphere / Urolead is proud to be part of the Repositive PDX comsortium.

Read more

> 2017 Oct

Acquisition of Urolead company.

Urosphere is pleased to announce its acquisition of Urolead company.

Read more